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DESIGN AND PRODUCTION OF A RECOMBINANT FliC-ANTIGEN CO-EXPRESSION
PLATFORM FOR INCREASED VACCINE EFFICACY

by

SARAH C. BOYD

Under the Direction of Sidney A. Crow, Jr.

ABSTRACT
The protein monomer of bacterial flagella, FliC, is known to stimulate human innate
immunity through activation of Toll-like receptor five. Linking native Salmonella FliC with
various antigens has demonstrated an increased immune response as compared to single antigen
presentation. To drastically reduce production time and allow for a more cost effective
recombinant vaccine adjuvant, a synthetic construct was created that enables genetic linkage of
FliC to other known antigens. The construct contains the necessary components for immune

system stimulation while the non-essential regions were replaced with commonly used restriction
enzyme recognition sites to aid in ligation with other antigens and cloning into various
expression vectors and hosts. After synthesis in the inducible expression vector pJ404, the
construct was transformed into competent BL21 E. coli and expression was confirmed through
SDS-PAGE, Western blot, and MALDI MS/MS. The cells were adapted to fermentation media
and re-screened for expression, and upon confirmation a 20-liter fermentation was conducted.
The resulting samples were analyzed for expression within the insoluble and soluble cellular
fractions to further optimize fermentation conditions. Once purified, this synthetic FliC will
serve as a platform technology for the standardized co-expression of the TRL5 activator with a
variety of antigens in both prokaryotic and eukaryotic systems.
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1
1.1

INTRODUCTION
Vaccines and The Human Immune Response
The global use of safe and effective vaccines is needed to ward against potentially harmful,

infectious diseases (Curtiss, 2002). According to the World Health Organization (WHO), 1.5
million children under the age of 5 died from vaccine-preventable diseases (VPDs) in 2012
(Global Immunization Data, 2014). Closer to home, the September 11, 2001 attacks on the
United States have increased governmental awareness and funding for defense programs against
bioterrorism involving both troops and civilians (Cohen and Marshall, 2001). With such foci,
diseases like measles, tetanus, yellow fever, and pertussis can all currently be avoided by
following proper vaccination protocols (CDC, 2006). The American Academy of Microbiology
(2005) has identified a variety of agents that pose a significant health threat for which there are
currently no licensed vaccines (Table 1). To significantly reduce the number of individuals
affected by preventable diseases and work toward disease eradication and terrorism protection,
vaccine development must be at the forefront of research and funding endeavors. To this end,
microbial expression systems can be designed to produce high yields of immunogenic vaccine
components in a short amount of time, reducing the overall process time and cost.
Vaccines simulate initial pathogen exposure through the delivery of known antigenic
cellular components, often with the addition of adjuvants to help surmount an immune response.
Current adjuvants include aluminum salts, oil-in-water emulsions, virosomes, and phospholipids
and serve to enhance the efficacy of weak antigens or to decrease the dosage required to activate
the immune system (Reed et al., 2013). Upon antigen recognition, the body begins a complex
signaling cascade to rid the bacteria, virus, toxins, or other non-self molecule through the innate
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and adaptive immune systems. The specialized adaptive immune system consists primarily of B
and T cells that, upon antigen-recognition and subsequent activation, recruit the production of
specific antibodies to clear the invader in a matter of days.

Table 1: Infectious agents that pose significant human health problems
with no licensed vaccines available (Vaccine Development: Current Status and
Future Needs. A report from the American Academy of Microbiology, 2005)

Sexually Transmitted
Agents

Respiratory Agents

Enteric Agents

Vectorborne Agents

Nosocomial Agents

Other Agents

Human Immunodeficiency Virus (HIV)
Human Papilloma Virus (HPV)
Herpes Simplex Virus (HSV)
Chlamydia trachomatis
Neisseria gonorrhoeae
Treponema pallidum
Respiratory Syncytial Virus (RSV)
Parainfluenza Virus
Human Metapneumovirus (HMPV)
Group A Streptococci
Chlamydia pneumoniae
Meningococcus B
Salmonella species
Shigella species
Escherichia coli (ETEC, EHEC, EPEC)
Helicobacter pylori
Noroviruses
Plasmodium falciparum
Dengue Fever Virus
Hantaviruses
Borrelia burgdorferi
Schistosoma species
Leishmania species
Hookworm
Staphylococcus aureus
Pseudomonas species
Enterococcus species
Gram negative enteric bacteria
Candida species
Hepatitis C, E viruses
Cytomegalovirus
Group B Streptococcus

The innate immune system detects non-self molecules through the activation of Toll-like
receptors (TLRs) within hours after initial exposure, leading to an inflammatory response and
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activation of adaptive immune cells. TLRs consist of a leucine-rich extracellular domain and a
highly conserved intra-cytoplasmic domain (Takeda et al., 2003) and are expressed on a variety
of lymphocytes, including dendritic and natural killer (NK) cells (Figure 1, Kaisho and Akira,
2002). Dendritic cells at the site of infection utilize TLRs to recognize non-self molecules,
causing these cells to migrate to nearby lymph nodes where they play a critical role in antigen
presentation and T-cell activation. Concurrently, activation of TLRs on NK cells leads to the
release of inflammatory cytokines and antimicrobial molecules. Through this interworking, the
innate immune system not only provides the first line of defense against invading
microorganisms, but it also recruits a more long-lasting, effective immunity.

Figure 1: Role of TLRs in Innate Immunity
Toll-like receptors are found on dendritic cells and play a crucial role in
antigen presentation and T-cell activation.

Mammals have ten highly conserved TLRs, each recognizing a specific pathogenassociated molecular pattern (PAMP) (Janeway, 1989). These PAMPs are evolutionarily stable
and critical to the organism’s survival. For example, TLR3 recognizes double stranded RNA,
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like that of retroviruses, while TLR4 recognizes the lipopolysaccharide of Gram-negative
bacteria (McInturff et al., 2006). This research, however, specifically focuses on the activation of
TLR5 by FliC, the major structural component of Salmonella flagellin (Hayashi et al., 2001).
1.2

FliC Structure and TLR5 Recognition
Bacterial flagella aid in locomotion and attachment and are therefore critical virulence

factors (Mobley et al., 1996). Attached to a molecular motor, each flagellar filament is made of
eleven protofilaments, comprised of flagellin monomers termed FliC, that have four domains
(D0, D1, D2, and D3) (Figure 2, Yonekura et al., 2003). The crystallized hairpin structure of each
monomer reveals these domains to be discontinuous (Namba et al., 1989), so that the linear
structure is: N terminus D0- D1- D2 - D3- D2 - D1- D0 - C terminus.
Comprising the D1 domain, the amino- and carboxyl- terminal ends of FliC are highly
conserved among Salmonella and other Gram-negative bacteria (Namba et al., 1989 and MimoriKiyosue et al., 1998) and are known to interact with TLR5 (Eaves-Pyles et al., 2001; Donnelly
and Steiner, 2002; Murthy et al., 2004) through three lateral helices (Figure 3, Yoon et al.,
2012). The D3 domain is neither conserved nor required for TLR5 activation, and is therefore
referred to the hypervariable region (Lino, 1977).
1.3

Flagellin as a Biological Adjuvant
Because FliC activates innate immunity through TLR5, it can serve as a biological vaccine

adjuvant when genetically linked to other antigens. Presentation of such heterologous proteins
could surmount a greater immune response than the singular counterpart. Ruth Arnon and
colleagues were the first to use flagellin as a biological adjuvant and others have since
demonstrated its capacity in this role (McEwen et al., 1992; Levi and Arnon, 1996; Ben-Yedidia
and Arnon, 1998; Ben-Yedidia et al., 1998; 1999a; 1999b). Since then, many other researchers
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have linked the TLR5 activator to known antigens (Table 2), establishing it as an effective
vaccine adjuvant.

Figure 2: Full Length Flagellin Protein Structure
Flagellin is comprised of four structural domains that aid in protein folding and TLR5 recognition.
Kaisho, T. and S. Akira. 2002. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta. 1589: 1-13.
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Figure 3: FliC interacts with TLR5
The D1 domain contains three highly conserved helices required for TLR5 activation.
Yoon, S., O. Kurnasov, V. Natarajan, M. Hong, A.V. Gudkov, A.L. Osterman, and A.I.Wilson. 2012.
Structural basis of TLR5-flagellin recognition and signaling. Science 335: 859-864.
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Table 2: Recombinant Flagellin Vaccines
Recombinant Flagellin Vaccine
Flagellin – Influenza hemagglutinin epitopes

McEwen et al., 1992
Levi and Arnon, 1996
Ben-Yedidia and Arnon, 1998
Ben-Yedidia et al., 1998
Ben-Yedidia et al., 1999a
Jeon et al., 2002
Adar et al., 2009

Flagellin – Influenza hemagglutinin globular head domain

Song et al., 2009

Flagellin – Influenza virus M2e ectodomain

Huleatt et al., 2008

Flagellin – Schistosoma mansoni epitope

Ben-Yedidia et al., 1999b

Flagellin – Campylobacter coli maltose-binding protein

Lee et al., 1999

Flagellin – Escherichia coli colonization factor I epitope

Flagellin – Escherichia coli heat-stable toxin

das Graças Luna et al., 2000
McSorley et al., 2000
Strindelius et al., 2004
Pereira et al., 2001

Flagellin – Tetanus toxoid

Lee et al., 2006

Flagellin – West Nile virus envelope protein

McDonald et al., 2007

Flagellin – Plasmodium antigen

Bargieri et al., 2008
Bargieri et al., 2010
Leal et al., 2013
Honko et al., 2006
Delaney et al., 2010
Mori et al., 2012
Weimer et al., 2009a
Weimer et al., 2009b

Flagellin – Yersinia pestis F1 antigen
Flagellin – Vaccinia virus L1R and B5R antigens
Flagellin – Helicobacter pylori antigen
Flagellin – Pseudomonas aeruginosa OprF epitope

1.4

Reference

First Generation FliC:Antigen Fusion Protein
Previous research within this lab linked native Salmonella FliC (Figure 4, Genbank

Acquisition: D13689) with antigens like those for Marberg and influenza.
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Figure 4: Full length flagellin 5' - 3' DNA sequence
5’ – 3’ DNA coding sequence of Salmonella flagellin. GenBank Acquisition: D13689

This
is approach utilized naturally ooccurring, blunt-ended
ended restriction enzyme recognition sites
throughout the fliC sequence but had several pi
pitfalls
tfalls that required unnecessarily complicated
steps during the cloning and expression processes. First, the DNA sequences of both flic and the
proposed antigens must be extensively analyzed ffor
or the presence of unwanted restriction enzyme
recognition sites. Iff the antigen were to be linked to FliC using the FatI enzyme, that site should
only be located once in both sequences to avoid an unwanted digest. If the site exists multiple
times, PCR must be utilized to construct a sequence without the site while maintaining the same
amino acid sequence. Redundancy of the genetic code (Figure 5) allows singlee nucleotide
substitutions to yield the same protein sequence as that containing an unwanted restriction
enzyme recognition site.
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Figure 5: The Genetic Code
There are 64 codons that code for only 20 amino acids.
Image Source: http://patentimages.storage.googleapis.com/WO2005021588A1/imgf000009_0001.png

For example, the DNA sequence 5’ ACG-AAT-TCC
TCC 3’ codes for the peptide sequence
Threonine-Asparagine-Serine
Serine but also contain
contains the EcoRI restriction recognition site,
site
5’ GAATTC 3’. To remove this unwanted site, one base must be substituted that would maintain
the aforementioned protein sequence.
quence. The corrected DNA sequence 5’ ACA-AAT
AAT-TCC 3’
maintains the polypeptide but lacks the EcoRI site. While this oversim
oversimplified
plified example is easily
corrected, removing an unwanted restriction enzyme recognition site is very time and labor
intensive, especially if the unwanted site is located within the middle portion
tion of a gene, requiring
the use of overlapping PCR (Figure 66).
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Unwanted RE Site

Figure 6: Overlapping PCR
Overlapping PCR can be used to remove unwanted restriction enzyme recognition sites. Primers are used to
introduce a needed mutation and to create a final fragment without the site.
Image adapted from: http://upload.wikimedia.org/wikipedia/commons/8/8b/Overlap_Extension_PCR.png

Secondly, it is commonly known that the use of blunt-ended restriction enzymes leads to
low ligation efficiency and transformation yield. It would be optimal to utilize enzymes that
leave “sticky ends,” ensuring greater recombination success with proper orientation. Lastly,
utilizing the native fliC sequence requires separate cloning strategies for each antigen of interest,
increasing overall time and the variety of needed enzymes. For these reasons, a more robust and
customizable FliC was desired to serve as reusable platform for the integration and co-expression
of many different antigenic proteins.
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2
2.1

MATERIALS AND METHODS
In silico Construct Design
The native DNA sequence of Salmonella typhimurium phase 1 flagellin (Figure 4) was

divided into each of its 7 subdomains by manually counting nucleotides (Figure 7). The
subdomains were then translated using the ExPASy online translator tool found at
http://web.expasy.org/translate/ (Figure 8) and BLASTED
(http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi?PAGE=Proteins) against the native sequence
for confirmation.

Figure 7: 5’ 3’ Native Salmonella FliC Domains - Color Coded
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DOMAIN
D0 (N)
D1 (N)

D2 (N)
D3

D2 (C)

D1 (C)
D0 (C)

AMINO ACID SEQUENCE
Met A Q V I N T N S L S L L T Q N N L N K S Q S A L G T A I E R L
SSGLRINSAKDD
AAGQAIANRFTANIKGLTQASRNANDGISIAQT
TEGALNEINNNLQRVRELAVQSANSTNSQSDLD
SIQAEITQRLNEIDRVSGQTQFNGVKVLAQDNT
LTIQVGANDGETIDIDLKQINSQTLGLDTLNVQ
Q
KYKVSDTAATVTG
YADTTIALDNSTFKASATGLGGTDQKIDGDLKF
DDTTGKYYAKVTVTGGTGKDGYYEVSVDKTNG
EVTLAGGATSPLTGGLPATATEDVKNVQV
A N A D L T E A K A A L T A A G V T G T A S V V K Met S Y T D N
NGKTIDGGLAVKVGDDYYSATQNKDGSISINTT
KYTADDGTSKTALNKLGGADGKTEVVSIGGKT
YAASKAEGHNFKAQPDLAEAAATTTE
NPLQKIDAALAQVDTLRSDLGAVQNRFNSAITN
LGNTVNNLTSARSRIE
D S D Y A T E V S N Met S R A Q I L Q Q A G T S V L A Q A N Q V
P Q N V L S L L R Stop

Figure 8: Amino Acid Sequences of Each FliC Domain

The D1 and D2 domains on both termini, responsible for immune system
recognition, were screened for the absence of all commercially-available restriction
enzyme sites by using the New England BioLabs Cutter located at
http://tools.neb.com/NEBcutter2/index.php and choosing the “0 cutters” option. These
resulting restriction enzymes were manually screened to remove those that leave blunt
ends, resulting in a list of restriction enzymes that do not cut within the sequence but will
leave sticky ends after cleavage. This list was further shortened to include only those
restriction enzymes that recognize multiples of 3 DNA nucleotides, aiding in frame
maintenance for future cloning (Figure 9).
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Figure 9: Possible Restriction Enzymes to be Used in the FliC Construct

To aid in ligation into commercially available expression vectors, the most commonly
used restriction enzymes were incorporated on the 5’ and 3’ ends, flanking the D2 domains. The
length of D3 domain/hypervariable region was maintained, although the DNA sequence was
altered so that one of the restriction enzyme recognition sites (Figure 9) was incorporated
between every 15 native nucleotides (Figure 18).

2.2

Construct Synthesis
The following 5’-3’ sequence of the Synthetic FliC Expression Platform (Figure 10) was
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optimized for expression in E. coli (Figure 11) and synthesized by DNA2.0
A2.0 (Menlo Park, CA) in
the pJ404 expression vector for a total recomb
recombinant length of 4140 base pairs:

Figure 10: Original 5'-3'
3' DNA sequence of FliC Expression Platform
Original 5’ – 3’ DNA sequence submitted to DNA2.0, before optimization for expression in E. coli

Figure 11:: Final 5'
5'-3' DNA Sequence of FliC Expression Platform
5’-3’
3’ DNA ssequence after codon optimization for expression in E. coli
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2.3

Transformation of BL21 E. coli Expression Strain
One tube of BL21 competent E. coli cells (New England Biolabs, C2530) was thawed on

ice for 10 minutes and mixed with 100ng of reconstituted pJ404 plasmid DNA containing the
FliC construct by gentle pipetting. The mixture was placed on ice for 10 minutes, transferred to a
42°C water bath for exactly 10 seconds, and placed back on ice for 5 minutes. Cells were
allowed to recover for 60 minutes in 950µL Super Optimal broth with Catabolite repression
(SOC) medium (2% w/v Tryptone, 0.5% w/v Yeast Extract, 10mM NaCl, 2.5mM KCl, 10mM
MgCl2, 20mM Glucose) shaking at 200rpm at 37°C. Meanwhile, Luria Bertani (LB) Agar
selection plates containing 100µg/mL ampicillin were warmed to 37°C. 100µL of transformed
cells and 100µL of each of three serial dilutions (10-1, 10-2, 10-3) were used to inoculate 4
separate warmed plates. The plates were allowed to sit upright on the bench top for one hour and
then incubated upside down at 37°C overnight.
2.4
2.4.1

Culture Maintenance
LB Glycerol Stocks
One resulting colony was picked from the undiluted sample and transferred to a 50mL

falcon tube containing 20mL LB broth with 100µg/mL ampicillin and allowed to grow at 37°C,
shaking at 200rpm overnight. 0.5mL of the overnight culture was added to 0.5mL filter-sterilized
60% glycerol, to achieve a 30% glycerol stock, and stored at -80°C.
2.4.2

Adaptation to Fermentation Media
100mL of E. coli Adaptation Media [(ECAM) per liter: 7.8g KH2PO4, 1.0g Citric Acid,

2.33g (NH4)2SO4, 1mL Trace Metal Solution, 1mL Thiamine HCl Solution, 40mL Glucose Stock
Solution, 13mL MgSO4 Solution, 0.5mL CaCl2 Solution; Trace Metal Solution: 900mL warm
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ddH2O, 5g EDTA, 10g FeSO4.7H2O, 2g ZnSO4.7H2O, 2g MnSO4.H2O, 0.2g CoCl2.6H2O, 0.1g
CuSO4.5H2O, 0.2g NaMoO4.2H2O, 0.1g H3BO3, dissolved and brought up to 1L with ddH2O,
autoclaved at 121°C for 30 minutes; Thiamine HCl Stock: 950mL ddH2O, 10g Thiamine HCl,
dissolved and made up to 1L with ddH2O and filter sterilized; Glucose Stock Solution: 700mL
ddH2O, 250g glucose, dissolved and made up to 1L with ddH2O and filter sterilized; MgSO4
Stock Solution: 900mL ddH2O, 78g MgSO4, dissolved and made up to 1L with ddH2O and filter
sterilized; CaCl2 Stock: 950mL ddH2O, 80g CaCl2, dissolved and made up to 1L with ddH2O and
filter sterilized] containing 100µg/mL ampicillin was warmed to 37°C and inoculated with a
1mL glycerol stock of the BL21 E. coli containing the recombinant pJ404 plasmid in a sterile
250mL flask. The culture was allowed to grow overnight at 37°C, shaking at 200rpm. The
following day, the OD600 was measured and the volume needed to yield an OD600 of 0.05 was
used to inoculate a 250mL flask containing 100mL ECAM with 100µg/mL ampicillin. Once an
OD600 of 0.8-1.2 was achieved, 0.5mL of the culture was added to 0.5mL filter-sterilized 60%
glycerol to achieve a 30% glycerol stock and stored at -80°C as ECAM-adapted cells.
2.5
2.5.1

Induction Analysis
Cytotoxicity Assay
A 1.0mL 30% glycerol stock of either BL21 housing recombinant pJ404 or BL21 with no

plasmid was used to inoculate two 50 mL falcon tubes containing 20mL LB broth with and
without 100µg/mL ampicillin, respectively. The cultures were incubated overnight at 37°C
shaking at 200rpm. A volume of these cultures was used to inoculate the following experimental
samples to an initial OD600 of 0.1 in 10mL LB broth plus antibiotics where appropriate in 15mL
falcon tubes: BL21 with no plasmid, Uninduced BL21 with recombinant pJ404, and Induced
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BL21 with recombinant pJ404. 1mM IPTG was added to the Induced culture once the OD600
reached 0.2. The cultures were allowed to grow for 300 minutes, shaking at 200RPM at 37°C,
and triplicate samples were taken every 30 minutes to measure the OD600.
2.5.2

Flask work
20mL of LB, 100mL of ECAM, and 100mL of Partially Defined E. coli Adaptation

Media [(PECAM) per liter: 10g Yeast Extract, 20g Tryptone, 3g KH2PO4, 6g K2HPO4, 2g
(NH4)2SO4, 1mL Trace Metal Solution, 0.02g Thiamine HCl, 20g Glucose, 1g MgSO4.7H20,
0.5mL CaCl2 Solution] each containing 100µg/mL ampicillin, were warmed to 37°C and
inoculated with a 1mL glycerol stock of the adapted BL21 E. coli containing the recombinant
pJ404 plasmid. The culture was allowed to grow overnight at 37°C, shaking at 200rpm. The
following day, the OD600 was measured and the volume needed to yield an OD600 of 0.05 was
used to inoculate 2, 250mL flasks with 100mL of each media containing 100µg/mL ampicillin.
Once an OD600 of 0.8-1.2 was achieved, an 80mM IPTG stock solution was added to one culture
to yield a final concentration of 1mM IPTG and the other culture served as the uninduced
control. After three hours of growth at 37°C, shaking at 200rpm, 10mL samples were taken from
each culture and placed in 15mL falcon tubes and stored for up to 8 hours at 4°C.
2.6
2.6.1

Fermentation with ECAM and PECAM
Inoculum preparation: ECAM
A 1mL adapted glycerol stock stored at -80°C was used to inoculate 250mL ECAM with

100µg/mL ampicillin in a sterile1L flask. The culture was incubated at 37°C while shaking at
200rpms for 14.5 hours. After, 2.8mL of the culture was transferred to 250mL ECAM with
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100µg/mL in a 1L flask to yield a starting OD600 of 0.1. After 6 hours the OD600 was 1.5 and
80mL of this culture was used to inoculate the vessel to a starting OD600 of 0.012.
2.6.2

Inoculum preparation: PECAM
250µL of a 1mL adapted glycerol stock stored at -80°C was used to inoculate 250mL

ECAM with 100µg/mL ampicillin in a sterile1L flask. The culture was incubated at 37°C while
shaking at 200rpms for 16 hours. After, 2.5mL of the culture was transferred to 250mL PECAM
with 100µg/mL in a 1L flask to yield a starting OD600 of 0.1. After 5 hours the OD600 was 5.0
and 20mL of this culture was used to inoculate the vessel to a starting OD600 of 0.012.
2.6.3

Vessel Set Up/ Fermentation Run: ECAM
The Biostat C 20L vessel was autoclaved with 2.5L of ddH2O and 1.5L of 10X EBAT

(750µL Antifoam, 22g KH2PO4, 10g Citric Acid, 45g (NH4)2SO4,10mL Trace Metal Solution,
10mL Thiamine HCl Solution) and 2L of 10X EBAT II (875mL Glucose Stock Solution, 130mL
MgSO4 Solution, 5mL CaCl2 Solution, 100mg/L ampicillin, dissolved and brought up to 2L with
ddH2O and filter sterilized) was added. After inoculation, a 10mL sample was taken and a
loopful was transferred to both a Nutrient Agar (NA) plate and a LB agar plate with 100µg/mL
ampicillin and incubated at 37°C to check for contamination and insure plasmid integrity,
respectively. The glucose concentration was 16.8g/L and the ampicillin concentration was
100mg/L.
The temperature was set at 30°C and the pH was maintained at 7.0. Dissolved oxygen
was maintained at 30% by cascade control with agitation, with a minimum value of 150rpm and
a maximum of 450rpm, and gas mix. Airflow was maintained 10 LPM.

19

2.6.4

Vessel Set Up/ Fermentation Run: PECAM
The Biostat C 20L vessel was autoclaved with 8.5L of double deionized water and 1.5L

of 10X PEBAT (10X PECAM with 750µL antifoam) was added. After inoculation, a 10mL
sample was taken and a loopful was transferred to both a Nutrient Agar (NA) plate and a LB agar
plate with 100µg/mL ampicillin and incubated at 37°C to check for contamination and insure
plasmid integrity, respectively. The glucose concentration was 19.6g/L and the ampicillin
concentration was 100mg/L.
The temperature was set at 30°C and the pH was maintained at 7.0. Dissolved oxygen
was maintained at 30% by cascade control with agitation, with a minimum value of 150rpm and
a maximum of 450rpm, and gas mix. Airflow was maintained 10 LPM.
2.6.5

Induction with 1mM IPTG
Upon glucose depletion as determined by the YSI, the feed rate was increased to confirm

0% net glucose accumulation. A 10mL, uninduced sample was taken and a filter-sterilized IPTG
solution was injected into the bioreactor to achieve a final concentration of 1mM. During the
ECAM fermentation, 10mL samples were taken at 1, 2, 3, 4,5, and 22 hours post induction for
analysis. During the PECAM fermentation, samples were taken at 1, 2, and 3 hours post
induction for analysis.
2.7

Preparation of Soluble, Insoluble, and Conditioned Media of Uninduced and Induced
Samples
3mL of each flask sample and 1mL of each fermentation sample were centrifuged at

14krpm for 5 minutes. The supernatant was removed as “Conditioned Media” and the pellet was
resuspended in 850µL Phosphate Buffered Saline (137mM NaCl, 12mM Phosphate, 2.7mM
KCl, pH 7.4) and sonicated on ice 3 times for 10 seconds (1 second on / 0.5 second off). The
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sonicated samples were spun at 14krpm for 15 minutes. The resulting supernatant was removed
as “Soluble Protein” and the pellet was resuspended in 850µL 50mM Tris, 8M Urea, pH 8.0 as
“Insoluble Protein.”
2.8

Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE)
10µL of 4x NuPAGE loading buffer (Novex) was added to 30µL of each sample,

vortexed, and heated at 80°C for 5 minutes. The samples were centrifuged at 14krpm for 5
minutes. 10µL of each sample was loaded into each well of a NuPAGE 4-12% Bis-Tris Gel
(Novex). The gel was run at 200 volts for 60 minutes in 1X MOPS SDS running buffer (Novex)
stained overnight in Coommassie Brilliant Blue, and destained in ddH20. The gel was imaged
using a Typhoon 9400 scanner (Amersham Biosciences) and Image Quant TL software (General
Electric).
2.9

Western Blot
The proteins separated by SDS-PAGE were transferred onto a nitrocellulose membrane

(Invitrogen, LC2000) for 1 hour at 30 volts. Gel-to-membrane contact was maintained
throughout by pressure from blotting pads and filter paper soaked in 1X Transfer Buffer [50mL
20X NuPAGE Transfer Buffer (Novex NP0006), 100mL methanol, 850mL ddiH20], sandwiched
within the Blot Module filled with 1X Transfer Buffer.
After, non-specific binding sites were blocked by incubating the membrane in 5% nonfat
milk in 1X TBST [100mL 10X TBS (0.2M Trizma-HCl, 1.5M NaCl, pH 7.6), 900mL ddH20,
1mL Tween-80], overnight shaking at 60rpm at 4°C. The membrane was washed 3 times for 5
minutes with 1X TBST shaking at 100rpm at 4°C, followed by an hour incubation shaking at
100rpm at 4°C with the Mouse Anti-Flagellin Primary Antibody (InvivoGen) diluted to 1:1000
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in 1X TBST. The membrane was then washed once with 1X TBST for 15 minutes, shaking at
100rpm at 4°C, followed by four more washes for 5 minutes, shaking at 100rpm at 4°C. The
membrane was then incubated for one hour, shaking at 100rpm at 4°C, with the Goat AntiMouse Antibody (Invitrogen, 62-6720), diluted to 1:10,000 in 1X TBST. The membrane was
then washed once with 1X TBST for 15 minutes, shaking at 100rpm at 4°C, followed by four
more washes for 5 minutes, shaking at 100rpm at 4°C.
The membrane was incubated with Chemiluminescence Reagent (PerkinElmer,
NEL103001EA) according to the manufacturer’s protocol and imaged using the
ImageQuant4000 (General Electric).
2.10 Protein Analysis via MALDI MS/MS
Bands of interest were excised from the stained SDS-PAGE gel and placed in 200µL
ddH20 and submitting to the protein sequencing facility in the Georgia State University Core
Facility for Matrix Assisted Laser Deabsorption Ionization (MALDI) mass spectrophotometry/
mass spectrophotometry (MS/MS) analysis.

3
3.1

RESULTS
Cytotoxicity Assay
Presence of the recombinant pJ404 plasmid in BL21 E. coli cells showed no negative

impact on growth as compared to that of cells without the plasmid (Figure 12). Also, the addition
of 1mM IPTG for protein induction at approximately 30 minutes post-inoculation also did not
negatively impact cell growth. The optical densities of the induced sample decreased after the
7th time point (210 minutes post-inoculation), however this slight decline was attributed to
variability within the shaker.
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3.2

Flask work: Induction in LB
SDS-PAGE and Western blot analyses of recombinant BL21 E. coli cells grown in 20mL

LB broth and induced with 1mM IPTG demonstrated target protein expression primarily in the
insoluble fractions (IP) after both 3 and 24 hours of induction (Figure 13). The major band
located in the insoluble fraction after 24 hours of induction was sequenced in the GSU Core
Facility using MALDI MS/MS. The resulting sequence matched that of native FliC, correlating
to 53 and 59 peptides on the N and C termini, respectively. The lower major band (~42kDa) was
also sequenced and demonstrated homology with OmpF, an outer membrane protein that is seen
in most of the E. coli protein work conducted in this laboratory. The third major band (~38kDa)
could be the result of degradation or truncation, cleavage, or an aggregation of proteins that
migrate more rapidly than their fully denatured counterparts. The faint band seen around 55kDa
could be attributed to dimerization of the synthetic FliC protein.
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Effects of Plasmid and Induction on
BL21 Cell Growth
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Figure 12: Effects of Plasmid and Induction on BL21 Cell Growth.
Cells were grown in LB Broth supplemented with 100µg/mL ampicillin at 37°C shaking at 200rpm for 300 minutes.
Triplicate samples were taken every 30 minutes and the OD600 values were measured and averaged.
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Figure 13: Induction in LB: Flask work.
SDS-PAGE
PAGE and Western Blot of protein samples extracted from BL21 with the recombinant
plasmid grown in LB broth at 37°C shaking at 200rpm
200rpm,, uninduced and induced with 1mM IPTG for 3 and 24 hours.
CM: Conditioned Media, SP: Soluble Protein, IP: Insoluble Protein
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3.3

Flask work: Induction in ECAM
After growth and induction in 100mL ECAM, SDS-PAGE analysis demonstrated a major

band in the insoluble fraction, a minor band in the soluble fraction, and a faint band in the
conditioned media (Figure 14). Western blot analysis confirmed strong expression within the
insoluble fraction after only 3 hours of induction with 1mM IPTG. The small, 38kDa protein
produced after growth in ECAM (Figure 14) and in LB (Figure 13) could be the product of
protein degradation, cleavage, or aggregation
3.4

Flask work: Induction in PECAM
Growth and induction in PECAM followed by SDS-PAGE and Western blot analyses of

cellular fragments resulted in a major protein band at approximately 45kDA, primarily in the
induced insoluble and soluble fractions, indicating strong induction of the FliC construct (Figure
15). As seen in Figures 13 and 14, growth in PECAM also produced a 38kDa protein, indicating
possible protein degradation or clumping.
3.5

Fermentation in ECAM
After a 20-liter fermentation in ECAM involving 22 hours of induction, the expected

45kDa protein was only present in the conditioned media after SDS-PAGE and Western blot
analysis (Figure 16). Full-length product was seen neither in the soluble nor insoluble fractions,
even after 22 hours of induction. However, a smaller band around 28kDa was confirmed in the
Western blot to be part of FliC and displayed a strong banding pattern in the insoluble fractions.
This sized fragment was not created in the LB (Figure 13), ECAM (Figure 14), or PECAM
(Figure 15) flask work. Also of note, the band commonly seen at 38kDA was only present in the
conditioned media.
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3.6

Fermentation in PECAM
A 20-liter fermentation in PECAM demonstrated target protein expression after 1,2, and

3 hours of induction with 1mM IPTG compared to the uninduced control, as seen in the SDSPAGE and Western blot in Figure 17. The ~38kDA protein present in the ECAM (Figure 14) and
PECAM (Figure 15) flask work but absent in the soluble and insoluble fractions of the ECAM
fermentation samples (Figure 16) was primarily expressed in the insoluble fractions after
fermentation using PECAM (Figure 17). To add, the 28kDA protein in the soluble and insoluble
fractions of the ECAM fermentation samples (Figure 16) was absent from the PECAM
fermentation samples (Figure 17).
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Figure 14: Induction in ECAM: Flask Work.
SDS-PAGE and Western Blot of protein samples extracted from BL21 with the
recombinant plasmid grown in ECAM at 37°C shaking at 200rpm, uninduced and induced with 1mM IPTG for 3 hours.
CM: Conditioned Media, SP: Soluble Protein, IP: Insoluble Protein
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Figure 15: Induction in PECAM: Flask Work
SDS-PAGE and Western Blot of protein samples extracted from BL21 with the
recombinant plasmid grown in PECAM at 37°C shaking at 200rpm, uninduced and induced with 1mM IPTG for 3 hours.
CM: Conditioned Media, SP: Soluble Protein, IP: Insoluble Protein
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Figure 16: ECAM Fermentation.
SDS-PAGE and Western Blot of protein samples extracted from BL21 with the
recombinant plasmid grown in 20 Liter ECAM Fermentation at 30°C and induced with 1mM IPTG
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Figure 17: PECAM FERMENTATION.
SDS-PAGE and Western Blot of protein samples extracted from BL21 with the
recombinant plasmid grown in 20 Liter PECAM Fermentation at 30°C and induced with 1mM IPTG
CM: Conditioned Media SP: Soluble Protein IP: Insoluble Protein
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4

DISCUSSION

4.1

Second Generation FliC-Antigen Co-Expression Platform
To effectively use FliC as a platform technology for the production of biological vaccine

adjuvants, a construct was created that allows antigenic proteins to be placed at the N-terminus,
C-terminus, and within the hypervariable region (Figure 18). The N-terminal and C-terminal D0
domains were replaced with commonly used restriction enzyme recognition sequences, as these
native sequences have not been demonstrated necessary for TLR5 activation, and the
hypervariable region was replaced with a synthetic sequence of restriction enzyme recognition
sites between every fifteen native nucleotides.
4.1.1

Rationale For N and C Terminal Sequences
Eaves-Pyles and colleagues (2001) were the first to study the effects of FliC mutations on

immune response and begin pinpointing the sequences necessary for inflammation. They created
a series of FliC protein-fraction fusions and tested for bioactivity, determining that the most
conserved amino and carboxyl termini are required for an immune response. In 2002, Donnelly
and Steiner worked to further isolate the FliC amino acids required for an inflammatory response
by creating a series of deletion and insertion mutants and measuring subsequent Interleukin (IL)8 release. They concluded that the last 121 residues of the N-terminal D1 and the first 12 residues
in D2 are required for inflammation. One year later Smith et al. also constructed a variety of FliC
mutants and determined that a deletion of the first 100 amino acids in the N-terminal D1 domain
resulted in complete loss of TLR5 activation and removing amino acids 416-444 in the C
terminus caused the same effect. In studying the mechanism by which some flagellated bacteria
circumvent the immune system, Andersen-Neissen and colleagues (2005) discovered that amino
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acids 89-96 within the N terminus are required for TLR5 activation. In 2012, Yoon et al.
continued this research by resolving the crystal structure of Zebrafish TLR5 complexed with
Salmonella FliC. It was determined that only the D1 domain interacts with the receptor.
Combining these data, removing the D0 domain should have no effect on TLR5 activation as
long as the D1 and D2 domains remain intact, and therefore the second generation FliC-Antigen
Co-expression platform contains popular restriction enzyme recognition sites at this location.
4.1.2

Rationale For Hypervariable Region Sequence
Eaves-Pyles et al. (2001) created a flagellin mutant containing the native N and C

terminal conserved domains and replaced the hypervariable region with an unrelated E. coli
DNA sequence and found this mutant to stimulate innate immunity like wild type flagellin. They
then speculated that the D3 domain allows the D1 and D2 domains to interact and activate TLR5.
Donnelly and Steiner (2002) confirmed that a large deletion within this region had no effect on
inflammation but an insertion led to decreased inflammation. This insertion might have a
consequence on the spatial relationship between the D1 and D2 domains, causing diminished
TLR5 activation. Liu et al. (2010) set out to definitively identify the role of the hypervariable
domain in innate immunity and adjuvancy by creating three distinct deletion mutants: ∆190-278,
∆220-320, ∆180-400, all of which lost their antigenicity. Based on these results combined, the
length of the D3 domain is required for proper protein folding and subsequent TLR5 activation
but the sequence is irrelevant. Therefore, the hypervariable domain of the synthetic FliC
construct is the same length as that of native flic but contains a 6 base pair restriction enzyme
recognition sequence every 15 nucleotides, allowing antigens of a variety of lengths to be
inserted into this region.
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Figure 18: Synthetic FliC Expression Platform
D0 and D3 domains were replaced with commonly used restriction enzyme recognition sites while D1 and
D2 remain for proper TLR5 activation.

4.2
4.2.1

Production in BL21 E. coli via pJ404
Synthesis in pJ404
The FliC-Antigen co-expression platform is capable of stable integration within a

variety of expression vectors, given that the most commonly used restriction enzymes are
located on the 5’ and 3’ ends of the platform DNA sequence. For initial synthesis, DNA2.0
provided an inducible expression vector, pJ404, which utilizes an IP-free T5 promoter. This
conscious choice to move away from the traditionally used T7 promoter safeguards the future
patentability of the construct, should the Brookhaven National Laboratory, under contract with
the U.S. Department of Energy, decide to patent and require licensure for the production of
transcripts utilizing the T7 promoter (Studier, 2005). The T5 promoter system was first
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described in 1985 by Gentz and Bujard, and has since been used and modified by many
companies. DNA2.0 has not patented their changes to the T5 promoter system and insures their
gene constructs are IP-free. The recombinant pJ404 was transformed into chemically competent
BL21 E. coli cells via heat shock. The BL21 strain is suitable for the expression of all non-T7
transcripts and is deficient of both Lon and OmpT proteases. Such strains are very useful for
the expression of recombinant proteins because the otherwise present proteases would cleave
misfolded and exogenous proteins, respectively.
4.2.2

Induction in LB

When BL21 cells transformed with pJ404 containing the synthetic FliC construct were
grown in LB broth and induced with 1mM IPTG, expression of the construct was seen primarily
in the insoluble fractions (Figure 13). This protein sequence was confirmed through MALDI
MS/MS and was used as an indicator band for all future induction studies. Although the amount
of protein loaded in each lane of the gel in Figure 13 is not exactly the same, each processed
pellet was resuspended in the same volume of buffer and therefore expression levels can be
compared across samples with some level of certainty. In this way, there was no apparent
increase in synthetic FliC production after 24 hours of induction, as compared to 3 hours of
induction. Also, there was no major shift in protein expression between the soluble to insoluble
fractions over time, as is often the case when proteins begin to form inclusion bodies and
aggregate.
To add, the synthetic FliC construct was either cleaved or formed fragments, as seen at
the 38kDA band on the SDS-PAGE and confirmed by interaction with the anti-FliC primary
antibody in the Western blot (Figure 13). This smaller version of the construct was present in all
three protein fractions but was most apparent in the insoluble fractions of both uninduced and
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induced samples. Although it is unclear why the cell would process the protein in this way, it is
plausible that the E. coli is truncating the monomer in an effort to form a functional flagellum.
4.2.3

Induction in ECAM

Because traditional media like LB is insufficient at maintaining high cell densities
common to large-scale production, a defined media containing ample amounts of glucose and
transcriptional cofactors was used for cell adaptation and fermentation. After two passes in
ECAM, the cells were glycerol stocked and used as inoculum for flask work and 20 liter
fermentations.
In the flask, recombinant cells grown in ECAM and induced with 1mM IPTG express the
synthetic FliC protein primarily in the insoluble fraction, but it is also seen in the conditioned
media and soluble fractions after 3 hours of induction (Figure 14). Interestingly, growth in
ECAM also promotes the formation of the 38kDA FliC fraction, similar to that produced in LB.
In ECAM, however, there is difference in expression levels between the uninduced and induced
samples that was not noted in the LB samples.
Using ECAM for a 20 liter fermentation, BL21 cells induced to express synthetic FliC
demonstrated production only in the conditioned media and this was confirmed through Western
blot (Figure 16). The 38kDA fragment noted in both LB (Figure 13) and ECAM (Figure 14)
flask work also only appeared in the conditioned media. To add, a new fragment around 28kDa
was produced primarily in the insoluble fractions but was also seen in the soluble samples. The
presence of a smaller protein could indicate that the cell is cleaving the FliC or that processing
conditions did not inactivate all proteases.
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4.2.4

Induction in PECAM

To promote the induction of full-length flagellin, the ECAM media was supplemented
with defined and scalable amounts of tryptone and yeast extract, according to Tabandeh et al.
(2004). The additional tryptone serves as a source of amino acids, promoting expression of
recombinant proteins. As seen in Figure 15, the 45kDa protein of interest was induced and
expressed in all three fractions after only 3 hours of induction in the flask, as compared to the
uninduced control. The 38kDa truncated FliC was also present in all three fractions but was
primarily produced in the soluble and insoluble fractions after induction.
Using PECAM in a 20 liter fermentation, full length synthetic FliC was produced in the
insoluble fractions after 1, 2 and 3 hours of induction (Figure 17). To add, the 38kDa, truncated
version was also present in the insoluble fractions but the smaller 28kDa fragment produced
during the ECAM fermentation was not. To promote the production of full length synthetic
FliC, and inhibit any truncated forms, PECAM serves as a viable candidate for future
fermentation experiments to optimize the concentration of IPTG, temperature, and oxygen levels.
4.3
4.3.1

Utilizing Other Expression Vectors and Hosts
pET Blue Vectors

If expression in a different vector or host is required for future applications, the
synthetic FliC construct can readily be cloned into the pETBlue-2 plasmid for expression in other
strains of E. coli (Novagen, Figure 19). Utilizing the 5’ restriction enzyme site NcoI and the 3’
site NotI, the construct can be ligated into the multiple cloning site of pETBlue-2. The NcoI site
is unique in that it also contains the start codon ATG, initiating transcription and translation of
any downstream DNA sequence.

37

Figure 19: pETBlue-2
pETBlue-2 vector for expression in E. coli (Novagen)

This system utilizes two cell types: one for cloning and one for expression. The NovaBlue
cloning host provides a quick blue/white screen for insertion within the multiple cloning site.
This cell type contains a lacZ ω-fragment that is complemented by the plasmid’s lacZ αfragment, producing a functional β-galactosidase that can degrade X-gal to produce a blue
colony. When the multiple cloning site is disrupted, the α-fragment is not produced and the cells
are rendered white. This quick screen circumvents the need for colony PCR, removing an extra
day from the total process time. After successful digest and ligation, white clones are further
confirmed through PCR and sequencing, and the pETBlue-2 plasmid is extracted and then
transformed into the DE3(tuner)pLacI E. coli expression host. Basal levels of protein expression
are kept to a minimum in this cell type through the use of a chromosomal T7 RNA Polymerase
that is under control of the lacUV5 promoter and subsequently repressed by the addition of 1%
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glucose in the media. IPTG can then be used to induce expression of genes placed within the
multiple cloning site.
4.3.2

Production in a Eukaryotic Host

In addition to E. coli, this platform can also be successfully produced and secreted by
Pichia pastoris through the use of the pGAPZα-B plasmid (Invitrogen, Figure19). This B-type
plasmid is one within a set of three (A, B, and C) for cloning in frame with an N-terminal αsecretion factor from Saccharomyces cerevisiae that is cleaved by the expression host.
This vector is industrially optimized for the constitutive expression of recombinant
proteins through stable integration within the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) promoter. Because this gene is a critical part of the glycolysis pathway, it is always
transcribed and translated. Therefore, transgenic proteins located within the GAPDH promoter
will also be constitutively expressed. The pGAPZα-B plasmid contains a region of homology for
crossover and subsequent expression of the gene of interest, Zeocin antibiotic resistance, and
GAPDH. Using this system, initial cloning occurs in E. coli through standard electroporation or
heat shock and proper ligation is confirmed using PCR. The recombinant plasmid is then
linearized and transformed into competent Pichia via homologous recombination.
4.4

Real World Applications/Relevance of Project
Production of a novel, recombinant FliC-Antigen co-expression platform will lead to a

variety of applications. First, this synthetic FliC can be used to increase the efficacy of currently
available vaccines or to increase the immune response of antigens previously found to not be
efficacious. Additionally, this construct can be used to simultaneously express several antigens,
incorporating them into a multivalent vaccine while cutting down on production costs and time.
For instance, the Diphtheria, Tetanus and Pertussis vaccine (DTaP) is currently given as one
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injection but is produced in three different hosts. Using the FliC platform, each antigen can be
expressed in the same host within the same protein structure to yield a more efficacious vaccine.
Lastly, using recombinant DNA technologies and producing antigenic proteins in microbial
systems drastically reduces the time and costs associated with the current egg-based vaccine
production which could be completely wiped out in the event of pandemic bird flu.

Figure 20:pGAPZ
pGAPZ vector for expression in Pichia pastoris (Invitrogen)

Work has already begun to incorporate a variety of antigens within this expression
platform. Of note, cloning strategies for incorporating antigenic StxB from Shigella
dysenteriae SD197, Stx2B from E. coli O157:H7, and HagA from Porphyromonas
gingivalis have been determined.
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5
5.1

CONCLUSION
Experimental Conclusions
The recombinant FliC-antigen co-expression platform has been successfully produced in

the bioreactor using both ECAM and PECAM. The former yields target protein expression in the
media, potentially reducing the overall purification processing time, while the latter demonstrates
expression in the insoluble cellular fraction. Under both conditions, truncated versions of the
protein were produced that interacted with the anti-FliC antibodies. These smaller fragments
could be a result of early translation termination or a byproduct of over-induction, and the
growth variables must be optimized for full-length protein production.
5.2

Future Work
The novel, recombinant FliC-antigen co-expression platform will be produced in both E.

coli and P. pastoris. The conditions for optimal fermentation and expression induction will be
determined and the protein will be produced in large quantities. From these preliminary studies,
it is clear that IPTG concentrations, media components, temperature, induction OD, and oxygen
levels must be optimized. These parameters will also need to be adjusted for each subsequent
antigen co-expressing clone. The resulting cell paste will then be subjected to Akta purification
using column chromatography to isolate only the FliC protein or Flic-Antigen chimera. This
purified product will be tested using the TLR5 cell assay to determine its immune response
efficiency. If the protein stimulates the immune response at the same level or greater than native
FliC, work will continue to incorporate other antigenic proteins within the sequence. In addition
to serving as a vaccine adjuvant, the synthetic FliC protein could potentially be sold as a research
chemical, once sufficiently purified and proven to active TLR5.
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